Holen Sie sich die Stockscreener-App
1.04
0.97%
0.01
Schlusskurs vom Vortag:
$1.03
Offen:
$1.0263
24-Stunden-Volumen:
84,599
Relative Volume:
1.60
Marktkapitalisierung:
$59.44M
Einnahmen:
$117.93M
Nettoeinkommen (Verlust:
$5.00M
KGV:
7.9148
EPS:
0.1314
Netto-Cashflow:
$-12.91M
1W Leistung:
+11.98%
1M Leistung:
+14.85%
6M Leistung:
-7.56%
1J Leistung:
-30.20%
1-Tages-Spanne:
$1.01
$1.07
1-Wochen-Bereich:
$0.9398
$1.16
52-Wochen-Spanne:
$0.68
$1.7698
Intercure Ltd Stock (INCR) Company Profile
Compare INCR vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
1.04 | 59.44M | 117.93M | 5.00M | -12.91M | 0.1314 |
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.21 | 38.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.09 | 31.90B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
542.66 | 23.03B | 3.17B | 1.29B | 1.01B | 27.09 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-05-18 | Hochstufung | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd Aktie (INCR) Neueste Nachrichten
InterCure Ltd. Actuals & Estimates (TASE:INCR) - TradingView
Price to earnings forward of InterCure Ltd. – TASE:INCR - TradingView
InterCure Ltd. Actuals & Estimates (BOATS:INCR) - TradingView
Price to sales forward of InterCure Ltd. – TASE:INCR - TradingView
InterCure Ltd (INCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InterCure secures $7.4M funding commitment, may rise to $18.6M - Investing.com UK
InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors. - marketscreener.com
InterCure Secures NIS 22 Million Private Placement to Fund Global Medical Cannabis Expansion - TipRanks
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds - markets.businessinsider.com
InterCure secures $7.4M funding commitment, may rise to $18.6M By Investing.com - Investing.com South Africa
InterCure (NASDAQ: INCR) lines up NIS 22–54 million private placement funding - Stock Titan
InterCure raises NIS 22M, with room to reach NIS 54M - Stock Titan
InterCure Ltd (INCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InterCure Ltd (INCR) Institutional Confidence - TradingKey
InterCure Ltd (INCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InterCure Ltd (INCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
InterCure Ltd (INCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InterCure Ltd (INCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InterCure Ltd (INCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InterCure Ltd (INCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InterCure Advances Global Push With Botanico Acquisition Tranche and U.S. Strategy Review - The Globe and Mail
InterCure completes Botanico acquisition and expands into U.S. medical cannabis - MMJDaily
InterCure Initiates Review of US Medical Cannabis Opportunities Following Federal Rescheduling - Cannabis Business Times
InterCure completes first tranche of Botanico acquisition By Investing.com - Investing.com South Africa
InterCure Ltd. Completes First Tranche of Botanico Acquisition to Enhance International Medical Cannabis Platform - Moomoo
InterCure (NASDAQ: INCR) advances Botanico deal and eyes U.S. medical cannabis - Stock Titan
InterCure Initiates Strategic Review of U.S. Medical - GlobeNewswire
U.S. cannabis shift prompts InterCure rethink and new launches in Germany - Stock Titan
Intercure Ltd. (INCR) Holds Near Support as Modest Gains Signal Stabilization AttemptRevenue Weighted - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates by Nearly 29%, Yet Stock Sheds ValueSegment Revenue Breakdown - newsline.com
INCR Q2 2023 Earnings: EPS Surpasses Estimates by 28.7%, Driving Stock HigherPositive Surprise Momentum - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates, Stock Declines Amid Broader Market HeadwindsAnalyst Coverage Count - newsline.com
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Beat Drives 12.15% Stock SurgeEnergy Earnings Report - newsline.com
INCR Q2 2023 Earnings: EPS Surpasses Estimates by 28.68%Debt Analysis Report - The Legal Advocate
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Surges Past Estimates, Stock RalliesSurprise Factor Analysis - The Legal Advocate
Intercure Ltd. Shares Surge Over 15% as Cannabis Sector Sees Renewed InterestThrowback Trade - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates as Profitability StrengthensProfit Warning Alert - The Legal Advocate
Intercure Ltd. (INCR) Rallies 5.57% as It Approaches Key Resistance LevelRSI Oversold Picks - The Legal Advocate
INCR Q2 2023 Earnings: Strong EPS Beat Highlights Operational EfficiencyEarnings Analysis - thelegaladvocate.com
Intercure Ltd. (INCR) Rallies 4.8%: Testing Key Resistance at $0.97Risk Reward Setups - newsline.com
INCR Q2 2023 Earnings: EPS Beat Surprises by 28.7% Despite Revenue UncertaintyAnalyst Drop Coverage - Město Břeclav
INCR Q2 2023 Earnings: EPS Surges Past Estimates as Company Delivers Strong Operational ResultsEarnings Trend Analysis - Newser
INCR Q2 2023 Earnings: EPS Surprises 28.68% Above Estimates Despite Negative Stock ReactionSocial Signal Watchlist - Newser
INCR (Intercure) beats Q2 estimates by 28% but shares fall 4% despite earnings surprise.AI Stock Signals - newser.com
How Intercure (INCR) performance reflects its true potential (Smart Money Flows) 2026-05-05Real Trader Insights - newser.com
InterCure Posts 2025 Revenue Growth, Positive Cash Flow as Recovery and Expansion Accelerate - The Globe and Mail
InterCure (NASDAQ: INCR) grows 2025 revenue to NIS 270M with positive cash flow - Stock Titan
InterCure Ltd. Reports NIS 270 Million Revenue and Positive Cash Flow for 2025 Amid Recovery Efforts - Quiver Quantitative
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow - Weekly Voice
Intercure LTD (INCR) Releases Q4 2025 Earnings: Revenue Up 43.8% but Company Remains Unprofitable - Quiver Quantitative
InterCure (INCR) 2025 20-F outlines licensing, war and market risks - Stock Titan
Finanzdaten der Intercure Ltd-Aktie (INCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.26%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):